Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells

ABSTRACT: Objective: Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment will be beneficial to improve the treatment of HER2-positive BC patients. In this study, we identified trastuzumab-responsive microRNAs that are involved in the therapeutic effects of trastuzumab. Methods and results: RNA samples were obtained from HER2-positive (SKBR3 and BT474) and HER2-negetive (MCF7 and MDA-MB-231) cells with and without trastuzumab treatment for 6 days. Next, we conducted a microRNA profiling analysis using these samples to screen those microRNAs that were up- or downregulated only in HER2-positive cells. This analysis identified miR-2

ORGANISM(S): Homo sapiens

SUBMITTER: Akira Myomoto 

PROVIDER: E-GEOD-38415 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress